Welcome to our dedicated page for Editas Medicine SEC filings (Ticker: EDIT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Editas Medicine, Inc. filings document regulatory disclosures for a clinical-stage genome editing company developing CRISPR-based in vivo medicines. Recent 8-K filings report operating results and financial condition, business highlights, EDIT-401 development disclosures, scientific data furnished under Regulation FD, and other events tied to CRISPR intellectual property matters.
The filing record also includes proxy materials covering board governance, executive compensation and equity awards, along with material-event reporting on a change in independent registered public accounting firm. These disclosures frame the company’s pipeline, capital resources, governance practices, risk areas and public-company reporting obligations.
Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation. The award covers 51,700 options to buy Editas Medicine common stock at an exercise price of $2.55 per share. The option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027, with an expiration date of June 16, 2036. Following this grant, Hirsch holds 51,700 stock options directly, and there were no open‑market stock purchases or sales reported in this filing.
Editas Medicine, Inc. director David Scadden received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and expire on June 16, 2036. They were granted on June 17, 2026 and are scheduled to vest in full on June 17, 2027. Following this grant, Scadden holds 51,700 stock options directly.
Editas Medicine director Elliott M. Levy received a grant of stock options covering 51,700 shares of common stock. The options have an exercise price of $2.55 per share and were granted on June 17, 2026. They are scheduled to vest in full on June 17, 2027 and will expire on June 16, 2036 if not exercised. Following this award, Levy holds 51,700 derivative securities directly.
Editas Medicine held its 2026 annual stockholder meeting, where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Connaughton received 28,660,181 votes for and 10,789,549 withheld, while Levy received 37,095,058 votes for and 2,354,672 withheld, in each case with 26,404,190 broker non-votes.
Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers, with 32,914,258 votes for, 6,322,885 against, 212,587 abstentions, and 26,404,190 broker non-votes. In addition, they ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 64,686,839 votes for, 774,471 against, and 392,610 abstentions.
Editas Medicine, Inc. senior vice president and chief financial officer Amy Parison reported an open-market sale of 464 shares of common stock on June 3, 2026 at a weighted average price of $2.7010 per share. According to the disclosure, the sale was carried out under a durable automatic sales instruction plan adopted on July 7, 2022 and was made to satisfy tax withholding obligations arising from vesting of restricted stock units on June 2, 2026, rather than as a discretionary trade. Following this transaction, she directly holds 14,970 shares of Editas Medicine common stock.
Editas Medicine CEO O'Neill Gilmore Neil reported an automatic, tax-related share sale. On June 3, 2026, he sold 15,380 shares of common stock at a weighted average price of $2.7011 per share, leaving 248,313 shares owned directly.
The sale was executed under a durable automatic sales instruction plan adopted on April 13, 2022, and was made to cover tax withholding obligations from restricted stock units that vested on June 2, 2026. The footnote states this was not a discretionary trade by the CEO.
Editas Medicine, Inc. executive Linda Burkly reported an open-market sale of common stock. She sold 731 shares on June 3, 2026 at a weighted average price of $2.7011 per share. After this transaction, she directly holds 67,297 shares of Editas Medicine common stock.
According to the footnotes, the sale was carried out under a durable automatic sales instruction plan adopted on July 3, 2023. The shares were sold to cover tax withholding obligations arising from restricted stock units that vested on June 2, 2026, and the filing states the trade was not discretionary.
Editas Medicine ownership disclosure: RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah report shared beneficial ownership of 8,889,000 shares of Editas Medicine common stock. The filing states this equals 5.8% of shares outstanding based on 153,461,838 shares outstanding as of May 27, 2026.
The Fund directly holds 8,889,000 shares and has delegated sole voting and dispositive power to RA Capital; the Reporting Persons disclaim beneficial ownership except for Section 13(d) purposes.
Editas Medicine, Inc. ownership disclosure: TCG Crossover III entities and Chen Yu report shared beneficial ownership of 15,798,999 shares of Common Stock, representing 9.9% of the class. The total counts include 11,111,111 issued shares plus 4,687,888 shares issuable upon warrants exercisable within 60 days. The filing cites 153,461,838 shares outstanding as of May 27, 2026 following an underwritten offering, and a combined basis of 158,149,726 shares when the exercisable warrants are included.
The reporting persons note a Beneficial Ownership Limitation that prevents exercise of certain warrants to the extent doing so would push ownership above 9.99%. The filing is a joint Schedule 13G by TCG Crossover Fund III, L.P., TCG Crossover GP III, LLC and Chen Yu and includes a joint filing agreement.
Editas Medicine reports a joint Schedule 13G showing Commodore Capital entities and two managing partners may be deemed to beneficially own 16,045,802 shares of common stock, comprising 8,889,000 shares plus rights to 7,156,802 shares underlying common warrants. The filing states ownership percentages are based on 153,461,838 shares outstanding as of May 21, 2026 and that a Beneficial Ownership Limitation of 9.99% applies. The report names Commodore Capital LP, Commodore Capital Master LP, Robert Egen Atkinson, and Michael Kramarz as filers and notes shared voting and dispositive power over the disclosed securities.